• Net profit up 2.8% at ₹184 crore in Q4 FY25 against ₹179 crore in the year-ago period.

• Revenue up 12.4% at ₹2,007 crore against ₹1,786 crore in Q4 FY24.

• EBITDA up 14.3% to ₹435 crore as compared to ₹381 crore in the year-ago quarter.

• Margin at 21.7% for Q4 FY25 against 21.3% in Q4 FY24.

The Board of United Spirits recommended a final dividend of ₹8 per share for the financial year 2024-25. The dividend, if approved, will be paid on or after September 4, 2025.

• Standalone net profit up 17.4% YoY to ₹451 crore against ₹384 crore.

• EBITDA at ₹505 crore in Q4 FY25, up 39.5% YoY from ₹362 crore in Q4 FY24.

• Margin at 17.1% in the reporting quarter as compared to 13.6% in the year-ago period.

• Revenue up 2.4% to ₹2,946 crore in Q4 FY25 from ₹2,666 crore in Q4 FY24.

• Net profit rose 22.6% to ₹19 crore in Q4 FY25 against ₹15.5 crore in the year-ago period.

• EBITDA at ₹33.6 crore for Q4 FY25, up 7.3% from ₹31.3 crore in year-ago quarter.

• Margin at 20.6% against 26.7% in Q4 FY24.

• Revenue at ₹163 crore, up 39% YoY from ₹117 crore.

• Net profit down 42.7% in Q4 FY25 at ₹97 crore against ₹169.3 crore in the year-ago period.

• Revenue rose 1.6% in Q4 FY25 to ₹3,758.6 crore as compared to ₹3,698.5 crore in Q4 FY24.

• EBITDA at ₹363 crore in the reporting quarter, down 24.6% YoY from ₹481.2 crore.

• Margin at 9.7% in Q4 FY25 against 13% in Q4 FY24.

The Board of Torrent Pharmaceuticals recommended a dividend of ₹6 per share for the financial year 2024-25 (FY25). The payout, if approved by shareholders, will be paid on or around August 4, 2025.

The Board also approved the plans to conduct a fundraise of up to ₹5,000 crore via QIP. It is now subject to the shareholders' approval at the company's AGM.

• Consolidated net profit up 11% YoY to ₹498 crore against ₹449 crore.

• Revenue rose 7.8% in Q4 FY25 to ₹2,959 crore as compared to ₹2,745 crore in the year-ago quarter.

• EBITDA at ₹964 crore, up 9.2% YoY from ₹883 crore.

• Margin at 32.6% in Q4 FY25 against 32.2% in Q4 FY24.

• Exceptional gain of ₹24 crore in Q4 FY25.

• Net profit up 1.3% at ₹221 crore in Q4 FY25 against ₹218 crore in the year-ago period.

• Revenue down 4% at ₹1,468 crore against ₹1,530 crore in Q4 FY24.

• EBITDA down 3.2% to ₹318 crore as compared to ₹329 crore in the year-ago quarter.

• Margin at 21.7% for Q4 FY25 against 21.5% in Q4 FY24.

The Board of Whirlpool of India has recommended a final dividend of ₹5 per share for the financial year 2024-25.

• Consolidated et profit up 53.6% YoY at ₹119 crore from ₹77.6 crore.

• EBITDA at ₹183 crore for Q4 FY25, up 27.4% from ₹144 crore in year-ago quarter.

• Margin at 9% against 8.3% in Q4 FY24.

• Revenue at ₹2,005 crore, up 15.6% YoY from ₹1,734 crore.

The Board of Directors of Gland Pharma recommended a final dividend of ₹18 per share for the financial year 2024-25 (FY25). The dividend, if approved, will be paid within 30 days from the date of the 47th Annual General Meeting.

The record date for the dividend eligibility is August 14, 2025.

• Revenue at ₹1424.9 crore versus ₹1,537.5 crore, DOWN 7.3%

• Net profit at ₹186.5 crore versus ₹192.4 crore, DOWN 3.1%

• EBITDA at ₹347.5 crore versus ₹358.6 crore, DOWN 3.1%

• Margin at 24.4% versus 23.3%

The board has recommended a final dividend on the equity shares of the company for the financial year 2024-25 at the rate of ₹8 per equity share of the face value of ₹2 each, out of the profits of the company.

The dividend, if approved by the members at the 32nd Annual General Meeting (AGM), will be credited within 30 days from the date of the AGM, Dixon said.

• Revenue at ₹10,293 crore versus ₹4,658 crore, UP 121%

• Net profit at ₹401 crore versus ₹95 crore, UP 321.16%

• EBITDA at ₹442.79 crore versus ₹182.45 crore, UP 142.7%

• Margin at 4.3% versus 3.92%

Solar Industries’ board has recommended a final dividend of ₹10 per equity share, i.e., 500% on the face value of ₹2 each, for the financial year 2024-25, subject to approval of shareholders at the Annual General Meeting.

The dividend, if approved by the members of the Company, will be paid within 30 days from the date of AGM.

• Revenue at ₹2,166.55 crore versus ₹1,610.71 crore, UP 34.5%

• Net profit at ₹322.23 crore versus ₹235.05 crore, UP 37%

• EBITDA at ₹539.67 crore versus ₹353.7 crore, UP 53%

• Margin at 24.9% versus 22%

Max Healthcare’s board recommended a final dividend of ₹1.5 per equity share (15% of the face value of ₹ 10 each) out of the profits of the financial year 2024-25. This is subject to the approval of the members of the company, which will be paid within 30 days from the conclusion of the forthcoming Annual General Meeting.

• Revenue at ₹1,910 crore versus ₹1,423 crore, UP 34%.

• Net profit at ₹319 crore versus ₹252 crore, UP 27%.

• EBITDA at ₹511.5 crore versus ₹382.6 crore, UP 33.7%.

• Margin at 26.79% versus 26.89%

“Hindalco delivered an all-time high performance in FY25, driven by strong operational resilience, cost discipline, and continued momentum across all our businesses. Our Aluminium Upstream business in India remained a strong anchor, complemented by robust growth in the downstream business. The copper business achieved a record EBITDA backed bytrong value-added product sales. Despite tighter scrap spreads, Novelis delivered a resilient performance through increased beverage can shipments.

 Hindalco is poised to enter a phase of accelerated growth backed by robust resource security in bauxite and coal and strengthened by strategic investments across aluminium and copper. Our copper smelter expansion, e-waste recycling and copper value-added products are progressing steadily, while in Speciality Alumina, we are scaling up with a differentiated, high-value portfolio.”

Aditya Birla Group's metal flagship Hindalco Industries also informed that it would acquire a 100% equity stake in EMMRL, a wholly owned subsidiary of Essel Mining & Industries Limited (EMIL), for a consideration of ₹48 lakh along with a net debt value of ₹1,131 crore.

This is subject to the approval of the shareholders of the company along with requisite approvals from the state government and central government, as may be applicable, it further said.

The board of Hindalco has recommended a dividend of ₹5 per equity share of ₹1 each for the financial year ended March 31, 2025, subject to the approval of shareholders at the Annual General Meeting (AGM).

• Revenue at ₹25,116 crore versus ₹22,140 crore, UP 13.4%.

• Net profit at ₹1,561 crore versus ₹1,412 crore, UP 10.5%.

• EBITDA at ₹2,999 crore versus ₹2,220 crore, UP 35.1%.

• Margin at 11.98% versus 10.03%

• Revenue at ₹402 crore versus ₹361 crore, UP 11.4%

• Net profit at ₹9 crore versus net loss of ₹1 crore

• EBITDA at ₹46.5 crore versus ₹32 crore, UP 45.3%

• Margin at 11.6% versus 8.9%

Commenting on the Q4 earnings, Zydus Lifesciences Managing Director Dr Sharvil Patel said:

“We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth. We look forward to continued execution success and deepening strategic partnerships to drive long-term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering.”

• Revenue from operations at ₹2,32,41.5 crore, up 19% over last year.

• Research & Development (R&D) investments for the year stood at ₹18,55.5 crore (8% of revenues).

• EBITDA for the year was ₹70,58.5 crore, up 31% YoY.

• EBITDA margin for the year stood at 30.4%, which is an improvement of 290 bps over the previous year.

• Net Profit, adjusted for exceptional items, was ₹47,45.1 crore, up 23% YoY.

• India-branded formulations business posted double-digit growth and outpaced the market growth.

• The consumer wellness business delivered robust double-digit growth aided by strong volume uptake.

• The US formulations business continued its upward journey with robust growth driven by volume expansion and new product launches.

• International markets business grew in double digits, driven by strong demand-led growth across geographies.

The pharma company’s Board recommended final dividend of ₹11 (at 1100%) per equity share of ₹1 each, subject to approval of the shareholders at the Annual General Meeting scheduled to be held on August 12, 2025.

• Revenue at ₹6,528 crore versus ₹5,533 crore, UP 18%.

• Net profit at ₹1,171 crore versus ₹1,823 crore, DOWN 1%.

• EBITDA at ₹2,126 crore versus ₹1,630.5 crore, UP 30.3%.

• Margin at 32.6% versus 29.5%

Shares of Zydus Lifesciences trades positive ahead of its March quarter earnings.

Here are some highlights of Zydus Life Q3 FY25 results:

Earnings before interest, taxes, depreciation and amortisation (EBITDA) of the company were up 26% YoY in the reporting quarter to ₹1,388 crore as against ₹1,102 crore in Q3 FY24. EBITDA margin was 26.3% for Q3 FY25.

The company posted a net profit of ₹3,355 crore for 9M FY25 as compared to the ₹2,677 crore reported in the year-ago period.

Zydus Lifesciences' EBITDA for 9M FY25 was at ₹4,933 crore, up 31.4% YoY from ₹3,754 crore in 9M FY24. EBITDA margin for 9M FY25 was at 29.5%.

In the Indian business, the company registered revenues of ₹1,947 crore in the December quarter, up 7% YoY. For the US formulations business, the registered revenues were at ₹2,410 crore in Q3 FY25, up 31% YoY.

In the company's international markets, revenues of the formulations business were up 16% YoY to ₹570 crore.

Shares of United Spirits are trading marginally higher ahead of its March quarter earnings announcement.

The stock is up 0.17% to ₹1,558.6 apiece on NSE.

United Spirits saw a 4.3% year-on-year (YoY) decline in its consolidated net profit to ₹335 crore in the December quarter of the 2024-25 financial year (Q3FY25), compared to ₹350 crore in the corresponding period last year.

Its revenue from operations stood at ₹7,732 crore, jumping 11.06% YoY from ₹6,962 crore in the third quarter of the 2023-24 fiscal year (Q3FY24).

United Spirits has a total market capitalisation of ₹1.03 lakh crore as of March 27, 2025, on the NSE.

Traders and investors will closely track shares of Dixon Technologies (India) on Tuesday, May 20, as the leading player in the electronic manufacturing services (EMS) space is slated to announce its March quarter earnings later in the day. The results will likely be released after market hours, i.e., 3:30 PM.

In the morning trade, the stock was trading at ₹16,968.45, up 2.35% on the BSE.

Founded in 1993, Dixon commenced manufacturing colour television in 1994. The company has now expanded its operations to various sub-segments of electronics. Dixon Technologies is primarily engaged in manufacturing products in the consumer durables, lighting, and mobile phone markets in India.

Market participants will watch out for the company's top-line and bottomline numbers, operational performance, dividend payout, management commentary and the outlook of the company as well as the industry.

Hindalco Industries, the flagship company of the Aditya Birla Group will announce its March quarter results today. The results are expected to announced afternoon hours followed by analyst/ investor meeting at 4:30 pm on 20 May.

Ahead of Q4 result announcement, Hindalco Industries shares are trading 1.8% higher in morning trades at ₹670.5 per share on NSE. So far in 2025, the stock has delivered over 11% return to investors.

As per experts, Hindalco Industries could report upbeat quarterly results. Its consolidated revenue is expected to increase 3-11% YoY to ₹57,850 to ₹62,350 crore, while its net profit could rise by 20-60% YoY to ₹3,850 to ₹5,100 crore on back on higher aluminium and alumina prices.

63 Moons Technologies

Apex Capital And Finance

Arvind SmartSpaces

Automotive Axles

Azad India Mobility

Bajaj Global

Bampsl Securities

Bansal Wire Industries

Betala Global Securities

Bhagyanagar India

Black Rose Industries

BLB

Bombay Potteries & Tiles

Chemcrux Enterprises

Classic Electricals

Comfort Intech

Continental Petroleums

Cosmo First

Danube Industries

Dev Labtech Venture

Dhunseri Investments

Dredging Corporation of India

Dhunseri Ventures

Dynavision

Easy Fincorp

Eco Hotels And Resorts

Electrotherm (India)

Emami Paper Mills

Electronics Mart India

Epuja Spiritech

Facor Alloys

Fineotex Chemical

Filtra Consultants and Engineers

Fortis Healthcare

Gabriel India

Ganga Pharmaceuticals

Gland Pharma

Gokul Agro Resources

Godawari Power and Ispat

Gujarat State Fertilizers & Chemicals

GTT Data Solutions

Gujarat Hy-Spin

Gujarat Inject Kerala

Gujarat Themis Biosyn

Gulshan Polyols

Hawa Engineers

Hemo Organic

Hindustan Appliances

Hindusthan National Glass & Industries

HT Media

Indong Tea Company

Indo Tech Transformers

Infra Industries

ISF

Jackson Investments

Jamshri Realty

Jasch Industries

Jayabharat Credit

Johnson Controls-Hitachi Air Conditioning India

Jenburkt Pharmaceuticals

Jasch Gauging Technologies

J. Kumar Infraprojects

As many as 142 companies will post their earnings number for the fourth quarter of the financial year 2024-25 on Tuesday, May 20. This includes Aster DM Healthcare, Coromandel Engineering Company, Dixon Technologies, EIH, Hindalco Industries, JK Tyre & Industries, Kirloskar Industries, Religare Enterprises, Torrent Pharmaceuticals, United Spirits, Zydus Lifesciences and others.